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Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG
(pTRG) in rectal cancer.
Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The
agreement between radiologist and pathologist was assessed with the weighted k test while the Kaplan–Meier method was used
to estimate survival outcomes.
Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-
operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair
agreement was found between mrTRG and pTRG when regression was classified according to standard five-tier systems (k¼ 0.24)
or modified three-tier systems (k¼ 0.25). Sensitivity and specificity of mrTRG 1–2 (complete/good radiological regression) for the
prediction of pathological complete response was 74.4% (95% CI: 58.8–86.5) and 62.8% (95% CI: 54.5–70.6), respectively. Survival
outcomes of patients with intermediate pathological regression (pTRG 2) were numerically better if complete/good regression
was also observed on imaging (mrTRG 1–2) compared to poor regression (mrTRG 3–5) (5-year recurrence-free survival 76.9% vs
65.9%, P¼ 0.18; 5-year overall survival 80.6% vs 68.8%, P¼ 0.22).
Conclusions: The agreement between mrTRG and pTRG is low and mrTRG cannot be used as a surrogate of pTRG.
Further studies are warranted to assess the ability of mrTRG to identify pathological complete responders for the adoption of non-
operative management strategies and to provide complementary prognostic information to pTRG for better risk-stratification after
surgery.
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On the basis of the high concordance between radiological data
and pathological findings, high-resolution magnetic resonance
imaging (MRI) has become the gold standard for rectal cancer
staging and assessment of baseline risk factors such as threatening/
involvement of the mesorectal fascia and extramural venous
invasion (EMVI) (Beets-Tan et al, 2001; Brown et al, 2003).
Routine use of MRI has led to the implementation of selective
management strategies including surgery alone for patients with
low-risk tumours (pT2, N0, and no risk factors) or neoadjuvant
therapy (i.e., long-course chemo-radiotherapy or short-course
radiotherapy depending on the need of tumour downsizing/
downstaging) followed by surgery for those at higher risk of
tumour recurrence (i.e., XT3 and/or Nþ stage, and/or other risk
factors) (Glimelius et al, 2013; NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines), 2017).
Magnetic resonance imaging has also played an increasingly
important role in the assessment of response to neoadjuvant
treatment and surgical planning (Beets-Tan and Beets, 2004;
MERCURY Study Group, 2007; Smith and Brown, 2008).
A number of imaging parameters have been proposed to assess
the degree of tumour response including linear, bi-dimensional or
volumetric changes of the primary tumour and T/N downstaging
(Kim et al, 2005; Kang et al, 2010; Yeo et al, 2010; Patel et al, 2012;
Yeo et al, 2012; Xiao et al, 2015). More recently, based on the
ability to distinguish between areas of residual cancer and
treatment-induced fibrosis (i.e., intermediate signal intensity and
low signal intensity, respectively, on T2-weighted images) and
estimate the relative proportion of these within the treated tumour
mass, an imaging-based, tumour regression scoring system (i.e.,
mrTRG) has been developed (Patel et al, 2011) that follows the
principles of the pathological tumour regression grading (pTRG)
proposed by Mandard et al (1994) and Dworak et al (1997).
The main advantage of mrTRG is that it does not rely on the
assessment of the resection specimens. The degree of tumour
regression on MRI can be assessed before any surgical procedure is
performed, this information potentially providing an opportunity
window to consider salvage pre-operative treatments if satisfactory
tumour regression is not achieved with standard therapy or
adoption of a non-operative management strategy if complete
response with no active residual cancer is diagnosed (Habr-Gama
et al, 2004; Maas et al, 2011; Renehan et al, 2016; Sclafani and
Brown, 2016; Sclafani and Chau, 2016). Furthermore, if appro-
priate training is undertaken, assessing tumour regression changes
on imaging scans may prove to be highly reproducible (Siddiqui
et al, 2016a) and potentially overcome some of the limitations of
pTRG including the need for accurate pathological sampling,
subjective interpretation and inter-observer variability (Lindebjerg
et al, 2011; Chetty et al, 2012a, b). Nevertheless, while the
prognostic value of pTRG in rectal cancer has been largely
confirmed and validated across a number of patient series and
using a variety of classification systems, fewer studies have analysed
the association between mrTRG and outcome in this setting
(Trakarnsanga et al, 2014; Siddiqui et al, 2016b). Also, little
information is currently available regarding the correspondence
between imaging and pathological tumour regression changes in
individual patients as well as the prognostic significance of mrTRG
in patients who undergo surgery and are therefore assessable for
pTRG.
In a recent report of Pooled Analysis of Individual Clinical and
Molecular Data of Two Trials of Neoadjuvant Chemotherapy in
High-Risk Rectal Cancer, EXPERT and EXPERT-C (PAN-EX), we
have shown that, in a population of high-risk, locally advanced
rectal cancer patients who were treated with an intensified
neoadjuvant treatment including induction chemotherapy followed
by chemo-radiotherapy, both mrTRG and pTRG were prognostic
for relapse-free survival (RFS), distant relapse-free survival (DRFS)
and overall survival (OS) in univariate analyses (Sclafani et al,
2016). However, in multivariate analyses, only mrTRG retained its
prognostic role. Here we report the correlation between mrTRG
and pTRG as assessed in individual patients from this study and
investigate the prognostic value of mrTRG in pTRG-defined
patient subgroups.
MATERIALS AND METHODS
PAN-EX was a pooled analysis of two academic phase II trials,
EXPERT and EXPERT-C (Sclafani et al, 2016). EXPERT was a
single-centre, single-arm, phase II trial conducted at The Royal
Marsden NHS Foundation Trust between 2001 and 2005.
EXPERT-C was an international, multicentre, randomised phase
II trial conducted at 12 sites across the UK, Sweden and Spain
between 2005 and 2008. Both studies were restricted to non-
metastatic rectal cancer patients with at least one of the following
high-risk features on high-resolution pelvic MRI: tumour p1mm
of the mesorectal fascia, extramural invasion 45mm (T3c/d), T4
stage, T3 tumour at/below levators. Additional eligibility criteria
included N2 stage (EXPERT) and EMVI (EXPERT-C) (Chau et al,
2006; Chua et al, 2010; Dewdney et al, 2012).
All patients received neoadjuvant treatment including four
cycles of induction CAPOX chemotherapy followed by capecita-
bine-based chemo-radiotherapy (54Gy in EXPERT and 50.4Gy in
EXPERT-C). Total mesorectal excision was performed 4–6 weeks
after completion of chemo-radiotherapy and followed by four
cycles of adjuvant chemotherapy (single agent capecitabine in
EXPERT and CAPOX in EXPERT-C). Cetuximab was also
administered throughout the study treatment in patients who
were randomised (1 : 1 ratio) to the investigational arm of the
EXPERT-C trial.
High-resolution MRI of the pelvis was done at baseline, at the
end of induction chemotherapy and 4 weeks after completion of
chemo-radiotherapy. All study MRI scans were centrally assessed
by one radiologist (G.B.) who was blinded to the pathological data
and long-term patient outcomes. MRI scans from EXPERT-C were
prospectively assessed while MRI scans from EXPERT were
retrospectively reviewed. mrTRG was defined as previously
reported (Patel et al, 2011). For the assessment of pTRG, the
recommendations by Dworak were followed (Dworak et al, 1997).
Generally, a minimum of five blocks or 5–8mm thick slices were
obtained from areas of macroscopic residual tumour and suspect
area of fibrotic tissue (if no macroscopic residual tumour),
respectively, in formalin fixed resected specimens. Three- to
5-mm thick, haematoxylin and eosin slides from each block were
prepared and examined. If no tumour was found on the first slide a
step section technique was used and three levels were cut on all
blocks from the tumour site; if still no tumour was found, the
whole of the tumour site and/or the fibrotic area was blocked.
pTRG was assessed by local independent pathologists who
were blinded to the imaging data. Assessment of pTRG was
done prospectively in EXPERT-C and retrospectively in EXPERT.
Both the imaging and the pathological system used to score TRG
in this study assess the relative proportion of fibrosis and
residual cancer and categorise tumour response using a five-tier
scale in the reverse order (Table 1). Only patients who were
assessable for both mrTRG after chemo-radiotherapy and pTRG
on resection specimens having undergone resection of the primary
tumour with a curative intent (R0/R1 resection) were included in
this analysis.
EXPERT and EXPERT-C were approved by the relevant
National Regulatory Agencies and Research Ethics Committee.
All patients provided written informed consent. The PAN-EX
study was approved by the Committee for Clinical Research at The
Royal Marsden NHS Foundation Trust.
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Statistical analysis. The strength of agreement between mrTRG
after completion of neoadjuvant treatment and pTRG on the
resection specimens was assessed using the weighted k test (k value
o0.20: poor agreement; k value¼ 0.21–0.40: fair agreement; k
value¼ 0.41–0.60: moderate agreement; k value¼ 0.61–0.80: good
agreement; k value¼ 0.81–1.00: very good agreement). This
analysis was conducted considering the pre-defined five categories
of tumour regression as well as converting the above described
five-tier regression systems into three-tier regression systems (i.e.,
pTRG 0–1 vs pTRG 2 vs pTRG 3–4 and mrTRG 4–5 vs mrTRG 3
vs mrTRG 1–2). Furthermore, correlation between prognostic
categories as defined by each regression system was also
investigated in an exploratory analysis. Sensitivity, specificity,
positive predictive value and negative predictive value of mrTRG
were calculated using a dichotomous classification for both mrTRG
(i.e., mrTRG 3–5 vs mrTRG 1–2) and pTRG (i.e., pTRG 0–3 vs
pTRG 4) to assess the ability of MRI to identify pathological
complete responders. Finally, the agreement between two radi-
ologists in the assessment of mrTRG (i.e., mrTRG 3–5 vs mTRG 1–
2) was analysed in a subset of randomly selected patients from the
EXPERT-C study using the weighted k test as above described.
Relapse-free survival and OS were calculated from date of surgery
to date of recurrence and death, respectively. Patients alive and
without evidence of tumour recurrence were censored at last follow-
up. Patients who died without tumour recurrence were censored at
the time of death. The Kaplan–Meier method was used to estimate
the survival outcome. Software used was SPSS 24 and Stata 14.
RESULTS
The PAN-EX study included 269 patients (105 from the EXPERT
trial and 164 from the EXPERT-C trial). Of these, 240 underwent
resection of the primary tumour with a curative intent (i.e., R0
resection in 233 cases while R1 resection in seven cases).
Radiological tumour regression on post-chemo-radiotherapy MRI
scan (i.e., mrTRG) and pathological tumour regression on surgical
specimens (i.e., pTRG) was reported for 215 and 208 patients,
respectively. A total of 191 patients (79.6%) were assessable for
both mrTRG and pTRG and represented the study population.
Patient demographics and baseline characteristics are shown in
Table 2. No significant differences were observed compared with
the overall PAN-EX population (data not shown). The median
time from the end of chemo-radiotherapy to the pre-operative MRI
scan was 4.1 weeks (IQR: 3.7–4.7). The median time from the end
of chemo-radiotherapy to surgery was 6.6 weeks (IQR: 5.9–7.6).
The median time from the pre-operative MRI scan to surgery was
2.6 weeks (IQR: 1.7–3.7).
In 64 out of 191 cases (33.5%) radiologist and pathologist
quantitated tumour regression using specular regression categories.
Overall agreement between mrTRG and pTRG using weighted
k analysis was 71.0% (k: 0.24) (Table 3). In the group of patients
for whom disagreement was due to a substantially more
pronounced regression on imaging than pathology specimens
(i.e., mrTRG 1/pTRG 0–2, mrTRG 2/pTRG 0–1, mrTRG 3/pTRG
0; n¼ 24) the median time from pre-operative MRI scan to surgery
was 2.7 weeks (IQR: 2.0–3.5). In the group of patients for whom
disagreement was due to a substantially more pronounced
Table 1. Classification system for mrTRG and pTRG
mrTRG pTRG
Description Grade Grade Description
No regression (intermediate signal intensity, same appearances as
original tumour)
mrTRG 5 pTRG 0 No regression
Slight regression (little areas of low signal intensity fibrosis or
mucin but mostly tumour)
mrTRG 4 pTRG 1 Dominant tumour mass with obvious fibrosis and/or vasculopathy
Moderate regression (low signal intensity fibrosis predominates
but there are obvious areas of intermediate signal intensity)
mrTRG 3 pTRG 2 Dominantly fibrotic changes with few tumour cells or groups (easy
to find)
Good regression (predominant low signal intensity fibrosis with no
obvious residual tumour signal)
mrTRG 2 pTRG 3 Very few (difficult to find microscopically) tumour cells in fibrotic
tissue with or without mucous substance
Complete regression (absence of tumour signal and barely visible
treatment related scar)
mrTRG 1 pTRG 4 No tumour cells, only fibrotic mass (total regression or response)
Abbreviations: mrTRG¼magnetic resonance tumour regression grade; pTRG¼pathological tumour regression grade.
Table 2. Demographics and baseline characteristics
N %
Gender
Male 108 56.5
Female 83 43.5
Age (yrs) (median & range) 63 31–80
ECOG performance status
0 81 42.4
1–2 110 57.6
Tumour differentiation
Well or moderately differentiated 163 85.3
Poorly differentiated 20 10.5
Missing 8 4.2
Tumour locationa
High rectum 69 36.1
Mid rectum 78 40.8
Low rectum 44 23.0
Length of tumoura (mm) (mean & s.d.) 54.4 15.8
T stagea
2 5 2.6
3b 144 75.4
4 42 22.0
N stagea
0 61 31.9
1 64 33.5
2 66 34.6
MRF threatened/involveda 111 58.1
EMVI positivea 136 71.2
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; EMVI¼ extramural venous
invasion; MRF¼mesorectal fascia; mrTRG¼magnetic resonance tumour regression grade;
pTRG¼pathological tumour regression grade; s.d.¼ standard deviation.
aAssessed by MRI (high: 410 cm from the anal verge; mid: 45–10 cm from the anal verge;
low: r5 cm from the anal verge).
b117/144 (81.3%) patients with T3 tumours had 45mm mesorectal infiltration (i.e., T3c or
T3d tumours).
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regression on pathology specimens than imaging (i.e., mrTRG
5/pTRG 2–4, mrTRG 4/pTRG 3–4, mrTRG 3/pTRG 4; n¼ 16) the
median time from pre-operative MRI scan to surgery was 2.1
weeks (IQR: 1.1–3.9). In the remaining patients (n¼ 151) this
interval was 2.4 weeks (IQR: 1.7–3.7). When only three categories
were considered for each regression system, 88/191 patients
(46.1%) were classified as having specular degree of tumour
regression on imaging and pathology for an overall agreement of
66.0% (k: 0.25).
Previous analyses of the PAN-EX study showed that patients
who had achieved mrTRG 1–2 after completion of chemo-
radiotherapy had a significantly better prognosis than the
remaining patient population without any difference between
mrTRG 3 and mrTRG 4–5. In contrast, the assessment of
pathological regression with the Dworak system allowed identifica-
tion of a group (pTRG 2) with an intermediate prognosis between
patients with pTRG 0–1 and those with pTRG 3–4 (Sclafani et al,
2016). 44 out of 87 patients (50.6%) belonging to the favourable
prognosis group based on the degree of radiological tumour
regression (mrTRG 1–2) were also found to have a good
pathological tumour regression (pTRG 3–4), the remaining
patients being classified as having a pTRG of 2 (31.0%) or 0–1
(18.4%). Among 104 patients with predicted poor prognosis due to
suboptimal tumour regression on pre-operative MRI scan (mrTRG
3–5), 49 (47.1%) were confirmed to have minimal pathological
tumour regression (pTRG 0–1), while 31 (29.8%) and 24 (23.1%)
showed a pTRG of 2 and 3–4, respectively. When a dichotomous
classification (i.e., pTRG 0–3 vs pTRG 4 and mrTRG 3–5 vs
mrTRG 1–2) was used to assess the ability of MRI to predict
complete regression, 32 out of 43 patients (74.4%) with
pathological complete response were correctly identified using
mrTRG. Sensitivity, specificity, positive predictive value and
negative predictive value of mrTRG were 74.4% (95% CI: 58.8–
86.5), 62.8% (95% CI: 54.5–70.6), 36.8% (95% CI: 26.7–47.8) and
89.4% (95% CI: 81.9–94.6), respectively. MRI scans of 25 randomly
selected patients from the EXPERT-C study were reviewed by two
radiologists (G.B. and S.B.) to assess inter-observer variability in
the assessment of complete/almost complete responders (i.e.,
mrTRG 1–2 vs mrTRG 3–5) and a very good agreement was
observed (weighted k agreement: 92.0%; k: 0.84).
The median follow-up of the study population at the time when
the analysis was conducted was 65.5 months (95% CI: 65.1–66.2;
range 1.5–122.0 months). Table 4 shows the outcome of pTRG-
defined patient subgroups according to the degree of radiological
tumour regression achieved after chemo-radiotherapy. While
mrTRG did not have any influence on the good prognosis of
patients with a pTRG of 3–4, it appeared to have a non-statistically
significant impact especially on the outcome of those who were
classified as having moderate pathological regression. In this group
5-year RFS and OS rates were 65.9% and 68.8%, respectively, if
mrTRG after chemo-radiotherapy was 3–5, and 76.9% (pairwise
comparison P value¼ 0.180) and 80.6% (pairwise comparison
P value¼ 0.220) if mrTRG after chemo-radiotherapy was 1–2.
Table 5 and Figure 1 show long-term outcomes of patients who
were classified by combining mrTRG and pTRG and splitting the
intermediate pathological tumour regression group (pTRG 2) into
two subgroups depending on the degree of tumour regression on
imaging.
DISCUSSION
To our knowledge, this is the largest study assessing the agreement
between an MRI-based tumour regression grading system and the
classical pTRG system as proposed by Dworak et al in a largely
homogenous series of locally advanced rectal cancer patients. The
results of our analysis overall suggest that limited correspondence
exists between regression groups/prognostic categories as identified
by such classification methods. Nevertheless, they support the
contention that mrTRG may potentially be used as an imaging
parameter to select good-prognosis patients who could be managed
with a non-operative approach following neoadjuvant treatment.
Furthermore, information on the degree of tumour regression on
the pre-operative MRI may be of prognostic value after surgical
resection in specific pTRG patient subgroups.
Monitoring treatment efficacy has a central role in the manage-
ment of cancer patients. Assessing the effects of treatment is not only
important to define treatment duration but it has also the potential to
Table 3. Comparison between mrTRG and pTRG
mrTRGa
5 4 3 2 1 Total
pTRGb 0 0 4 4 1 0 9
1 4 17 20 13 2 56
2 0 12 19 23 4 58
3 0 6 8 24 4 42
4 0 5 5 12 4 26
Total 4 44 56 73 14 191
Abbreviations: mrTRG¼magnetic resonance tumour regression grade; pTRG¼
pathological tumour regression grade.
amrTRG 1 and mrTRG 5 indicate complete radiological regression and no radiological
regression, respectively.
bpTRG 4 and pTRG 0 indicate complete pathological regression and no pathological
regression, respectively.
Table 4. Prognostic impact of mrTRG in specific pTRG patient subgroups
Outcome measure pTRG/mrTRG subgroup
n Events/n
subjects
5-year survival
(95% CI)
Hazard ratio
(95% CI) P value Pairwise p value
RFS
1. pTRG 0–1/mrTRG 3–5 23/49 57.1 (43.2–71.0) 1.0 (0.023) 1 vs 2
2. pTRG 0–1/mrTRG 1–2 6/16 73.3 (50.9–95.6) 0.64 (0.26–1.60) 0.34 0.391
3. pTRG 2/mrTRG 3–5 11/31 65.9 (48.7–83.1) 0.85 (0.41–1.76) 0.65 3 vs 4
4. pTRG 2/mrTRG 1–2 6/27 76.9 (60.6–93.2) 0.45 (0.18–1.11) 0.081 0.180
5. pTRG 3–4/mrTRG 3–5 3/24 87.3 (73.8–100) 0.25 (0.07–0.84) 0.025 5 vs 6
6. pTRG 3–4/mrTRG 1–2 8/44 88.5 (78.9–98.1) 0.30 (0.14–0.68) 0.004 0.974
OS
1. pTRG 0–1/mrTRG 3–5 21/49 63.1 (49.6–76.6) 1.0 (0.053) 1 vs 2
2. pTRG 0–1/mrTRG 1–2 5/16 80.0 (59.8–100) 0.57 (0.21–1.52) 0.260 0.301
3. pTRG 2/mrTRG 3–5 10/31 68.8 (51.7–85.9) 0.83 (0.39–1.80) 0.638 3 vs 4
4. pTRG 2/mrTRG 1–2 5/27 80.6 (65.3–95.9) 0.45 (0.17–1.20) 0.110 0.220
5. pTRG 3–4/mrTRG 3–5 3/24 91.7 (78.2–100) 0.30 (0.09–1.00) 0.050 5 vs 6
6. pTRG 3–4/mrTRG 1–2 7/44 90.7 (82.1–99.3) 0.31 (0.013–0.72) 0.007 0.771
Abbreviations: CI¼ confidence interval; mrTRG¼magnetic resonance tumour regression grade; OS¼overall survival; pTRG¼pathological tumour regression grade; RFS¼ recurrence-free
survival.
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provide useful prognostic information and guide subsequent
therapeutic and/or follow-up strategies. This is certainly relevant to
rectal cancer where neoadjuvant therapy is routinely used for locally
advanced tumours to increase the chances of surgical resection with
clear margins and/or to reduce the risk of local recurrence
(Braendengen et al, 2008; Sauer et al, 2012). Meticulous assessment
of the surgical samples was proposed more than two decades ago to
provide a semi-quantitative estimate of the degree of tumour
regression with prognostic implications (Mandard et al, 1994;
Dworak et al, 1997) and pTRG is now regularly included in
pathology reports. Nevertheless, its clinical usefulness remains limited
for a number of reasons. First of all, assessment of response to
neoadjuvant treatment by pTRG is only possible in patients who
undergo resection and only after a surgical procedure has been
performed. Furthermore, the potential of pTRG to capture the
heterogeneity of tumour response to chemo-radiotherapy and
overcome the simplistic distinction between complete responders
and noncomplete responders has inevitably translated into a
relatively low inter-observer reproducibility of the same (Lindebjerg
et al, 2011; Chetty et al, 2012a, b). The availability of a variety of
pTRG scoring systems has enhanced this inconvenience and also
reduced comparability between series. Finally, despite a promising
premise, the impact of pTRG on the management of rectal cancer is
still limited as there is still no evidence to suggest that tailoring post-
operative treatments based on the degree of pathological regression
may improve outcome.
Advances in imaging have provided an opportunity to use
novel, alternative methods for the assessment of tumour response
to neoadjuvant chemo-radiotherapy. mrTRG has recently emerged
as a dynamic, non-invasive, surrogate method for the assessment of
tumour regression following neoadjuvant treatment and before
surgical resection (Patel et al, 2011). Studies have shown its ability
to predict pathological findings on the surgical specimens as well as
long-term prognosis (Patel et al, 2011; Shihab et al, 2011; Bhoday
et al, 2016; Siddiqui et al, 2016b). Also, both in routine practice
(Sclafani et al, 2016) and adaptive clinical trials (NCT02704520)
mrTRG has been increasingly used as a decision-making tool for
patient management following completion of standard neoadju-
vant chemo-radiotherapy.
Nevertheless, one of the questions that remain unanswered
regarding mrTRG is whether and to what extent this truly reflects
the degree of pathological regression that will be observed
once surgery has been carried out. In this study we have shown
that, even though tumour regression on imaging is measured
according to a five-tier scoring system mirroring the scoring system
that is used for the assessment of pathological regression, the
agreement between radiologists and pathologists is overall limited.
This did not appear to be any better when regression groups with
similar prognosis across the two scoring systems (instead of the pre-
defined categories of regression) were directly compared. While
these results are in line with other studies (van den Broek et al, 2017)
and appear to suggest that mrTRG cannot be considered as an
accurate predictor of pTRG, it should be noted that the time interval
between chemo-radiotherapy and surgery in our series was longer
than that between chemo-radiotherapy and MRI (difference between
median values: 2.5 weeks) this possibly accounting for some of the
observed discrepancies. Response to chemo-radiotherapy is a
continuum process with the peak of tumour regression being
estimated to occur B8–11 weeks after treatment completion
(Sloothaak et al, 2013; Probst et al, 2015; Sun et al, 2016). Therefore,
Table 5. Survival outcomes by combining mrTRG and pTRG
Outcome measure pTRG/mrTRG subgroup n Events/n subjects 5-year survival (95% CI) Hazard ratio (95% CI) P value
RFS
pTRG 0–1/mrTRG any
pTRG 2/mrTRG 3–5
40/96 62.7 (52.9–72.5) 1.0 0.001
pTRG 2/mrTRG 1–2
pTRG 3–4/mrTRG any
17/95 86.0 (78.9–93.1) 0.37 (0.21–0.66)
OS
pTRG 0–1/mrTRG any
pTRG 2/mrTRG 3–5
36/96 67.5 (57.9–77.1) 1.0 0.003
pTRG 2/mrTRG 1–2
pTRG 3–4/mrTRG any
15/95 88.1 (81.4–94.8) 0.39 (0.22–0.72)
Abbreviations: CI¼ confidence interval; mrTRG¼magnetic resonance tumour regression grade; OS¼overall survival; pTRG¼pathological tumour regression grade; RFS¼ recurrence-free
survival.
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Figure 1. Kaplan–Meier curves for recurrence-free survival (A) and overall survival (B) by combining mrTRG and pTRG.
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it is possible that the early timing of MRI assessment in this patient
population may have precluded the anticipated category shift in
tumour regression and ultimately affected the agreement between
mrTRG and pTRG. In support of this contention, the proportion of
study patients achieving complete regression on resection specimens
was almost twice as high as that on imaging (i.e., 13.6% vs 7.3%). On
the other hand, while cases where poor pathological regression was
reported despite complete or almost complete absence of inter-
mediate signal intensity on pre-operative imaging could raise the
possibility of early tumour regrowth, the median interval between
MRI scan and surgical resection in this patient subgroup (2.7 weeks
vs 2.5 in the overall population) mitigates against this hypothesis.
We believe that these cases are more likely to be secondary to a
reduced specificity of MRI after neoadjuvant treatment (Memon
et al, 2015). Finally, it is also possible that the investigational,
intensified neoadjuvant treatment strategies that were used in the
PAN-EX study might have had an impact on the limited
correspondence between mrTRG and pTRG. For instance, in
contrast with what we have previously reported in studies with
conventional chemo-radiotherapy (Patel et al, 2011), only two
(instead of three) mrTRG prognostic groups could be identified in
the PAN-EX population where a regression category with
intermediate prognosis was lacking (Sclafani et al, 2016).
Even accounting for the above mentioned biases, one could argue
that the lack of substantial correspondence between tumour regression
as identified by imaging and pathology may undermine the clinical
value of mrTRG. It should be noted, however, that the prognostic role
of this imaging parameter has already been validated in a number of
series and in the PAN-EX study itself mrTRG (but not pTRG)
emerged as an independent factor for RFS, DRFS and OS in the
curatively resected population (Shihab et al, 2011; Bhoday et al, 2016;
Sclafani et al, 2016; Siddiqui et al, 2016b). Moreover, the main value of
using mrTRG is to provide a non-invasive imaging tool to identify
those patients who are more likely to achieve complete response to
treatment and therefore may be spared from surgery (Habr-Gama
et al, 2004; Maas et al, 2011; Renehan et al, 2016). In our series, the
sensitivity and specificity of mrTRG to identify pathological complete
response was 74.4% and 62.8%, respectively. While these data appear
less encouraging compared to previous reports (Bhoday et al, 2016), it
should be noted that in this study more stringent criteria (i.e., mrTRG
1–2) for the definition of complete response according to imaging
were used excluding mrTRG 3 tumours that may actually continue to
regress beyond the date of MRI scan. Furthermore, repeat assessment
of mrTRG on serial MRI scans to follow the evolution of tumour
regression over time is more clinically relevant than a snapshot of
mrTRG at a single time point and likely to increase the overall
accuracy of this imaging marker in predicting pathological complete
response. In this regard it is worth noting that, using a subset of study
patients, we have confirmed the results of previous studies regarding
the reproducibility of mrTRG (Siddiqui et al, 2016a) and showed a
very good agreement between radiologists in the assessment of
complete or almost complete tumour regression.
The results of our study suggest that, despite similar nomen-
clature and categorisation system, mrTRG and pTRG are not
interchangeable parameters but have the potential to provide
complementary information regarding sensitivity of the primary
tumour to neoadjuvant treatment and overall outcome. Of interest,
patients who had not achieved substantial/complete regression
according to the pathology report could be further stratified for the
risk of tumour recurrence and death based on the degree of tumour
regression as assessed on imaging at the end of chemo-radiotherapy.
This effect appeared possibly stronger for those who were
categorised as having a pTRG of 2 and therefore expected to have
intermediate prognosis. While these data are certainly intriguing, it
should be acknowledged that the impact of mrTRG on the prognosis
of patients with sub-optimal pathological regression was only
numerical but not statistically significant possibly due to the small
sample size of the study. Larger series are needed to confirm these
hypothesis-generating findings and better assess the clinical
relevance of mrTRG in patients who undergo surgical resection
and are therefore assessable for standard pTRG.
Intra- and inter-observer reproducibility is an established caveat
of semi-quantitative scoring systems. A number of studies have
demonstrated that achieving consensus on the degree of tumour
regression in resection specimens among pathologists is particu-
larly challenging (Lindebjerg et al, 2011; Chetty et al, 2012a, b).
While the assessment of pTRG by local pathologists suggests that
the pathological data from PAN-EX are reflective of real-world
practice, the lack of a centralised review (in contrast with the
radiological assessment) may have introduced significant biases.
mrTRG appears to be less prone to inter-observer variability
among specifically trained radiologists (Patel et al, 2011), as
confirmed by the analysis of a subset of patients from our study.
The assessment of mrTRG, however, may be still potentially
affected by a certain degree of subjective interpretation. Therefore,
the results of our study should be interpreted in view of these
inherent limitations. It is possible that the findings here reported
may not be confirmed in series from other institutions. Never-
theless, the mrTRG scoring system, which was first proposed by
our group, has been routinely used for several years at our
institution and pTRG in PAN-EX was assessed by highly
experienced pathologists, thus increasing the reliability of our
study. Also, the use of a weighted k test to compare radiological
and pathological assessment should have accounted for some inter-
observer variability and increased the generalisability of our results.
Finally, given the similarities between all the available pTRG
scoring systems both in terms of classification criteria and
prognostication (Trakarnsanga et al, 2014), it is unlikely that
classifying pathological tumour regression according to a different
method would change the outcome of the analysis.
In conclusion, while the retrospective design of the study and
the above mentioned caveats recommend caution in the inter-
pretation of our findings, this analysis suggests that the agreement
between mrTRG and pTRG is low and thus mrTRG cannot be
considered as a reliable surrogate imaging marker of pTRG in
locally advanced rectal cancer patients who undergo an intensified
neoadjuvant treatment. Nevertheless, given the ability to provide a
non-invasive assessment of tumour response, mrTRG remains a
potential tool for the implementation of dynamic, risk-adapted,
neoadjuvant treatment strategies following standard chemo-radio-
therapy including deferral of surgery/watch and wait or further
(i.e., sequential/salvage) therapy. Assessing the degree of tumour
regression on pre-operative MRI scans may potentially serve also
as a useful parameter to combine with conventional pathological
factors to refine prognostication and possibly guide adjuvant
treatments/follow-up strategies after surgical resection. It should be
noted, however, that mrTRG is only one of the available methods
to assess and categorise tumour response to neoadjuvant treatment
and its significance should be interpreted in the context of other
well-established imaging parameters. Furthermore, mrTRG is
regularly reported only in a limited number of centres and further
studies to investigate its clinical applications are warranted.
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